Reprint
Marine Compounds and Cancer 2020
Edited by
June 2021
480 pages
- ISBN978-3-0365-0630-2 (Hardback)
- ISBN978-3-0365-0631-9 (PDF)
This is a Reprint of the Special Issue Marine Compounds and Cancer that was published in
Biology & Life Sciences
Chemistry & Materials Science
Medicine & Pharmacology
Summary
The very first marine-derived anticancer drug, Cytarabine (aka Ara-C, Cytosar-U®), was approved by the FDA in 1969 for the treatment of leukemia. At the beginning of 2021, the list of approved marine-derived anticancer drugs consists of nine substances, five of which received approval within the last two years, demonstrating the rapid evolution of the field. The current book is a collection of scientific articles related to the exponentially growing field of anticancer marine compounds. These articles cover the whole field, from agents with cancer-preventive activity, to novel and previously characterized compounds with anticancer activity, both in vitro and in vivo, as well as the latest status of compounds under clinical development.